Children’s ZYRTEC® Clinical Data
Children’s ZYRTEC® 5 mg makes a significant impact on allergy symptoms1
In patients ages 2 to 6 years with seasonal allergic rhinitis (SAR), Children’s ZYRTEC® provides a powerful symptom response1
66% of children demonstrated ≥50% improvement from baseline SAR symptoms over 2 weeks.1
Randomized, placebo-controlled study of children aged 2 to 6 years with SAR during a 2-week period. Primary endpoint was the change in total symptom score complex from baseline.
*Significant vs placebo.
†ZYRTEC® 5 mg vs placebo ratio at ≥50% reduction is 1.84-fold.
Reference: 1. Data on file, Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division.
Learn more about Children's ZYRTEC®
View Children's ZYRTEC® tolerability profile
Help educate children and caregivers about allergies with an educational brochure and storybook.